IDA
EFTR

Intelligence Driven Advisers’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Intelligence Driven Advisers’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,951
Closed -$24.4K – 106
2022
Q4 		$24.4K Buy
+1,951
New +$24.8K ﹤0.01% 99

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $26.2B AUM
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOA
Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return

Intelligence Driven Advisers's EFTR Position: Q1 2023 in Review

Intelligence Driven Advisers sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2023, closing a stake of 1,951 shares — an estimated $24.4K sold.

Intelligence Driven Advisers first reported a position in EFTR in Q4 2022 and held it in 1 quarter. The position peaked at $24.4K in Q4 2022. 26 funds tracked by Wall St. Rank hold EFTR as of Q1 2023.

  • Intelligence Driven Advisers reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Intelligence Driven Advisers sold 1,951 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $24.4K.
  • Intelligence Driven Advisers first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Intelligence Driven Advisers's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $24.4K in Q4 2022.
  • 26 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Intelligence Driven Advisers's 13F filing for Q1 2023, filed 11 May 2023.